You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨歌禮制藥-B(01672.HK)三日累漲近30% 旗下拳頭產品利托那韋是輝瑞Paxlovid的重要成分之一
格隆匯3月18日丨歌禮制藥-B(01672.HK)漲近17%,報5.47港元創約兩個月以來新高,總市值59億港元。昨日,聯合國支持的日內瓦藥品專利池(MPP)組織宣佈,已與35家藥企簽署協議,允許其生產輝瑞新冠口服藥Paxlovid成分之一奈瑪特韋(nirmatrelvir)原料藥或製劑。據悉,輝瑞的Paxlovid由兩片150mg的奈瑪特韋片和一片100mg的利托那韋片形成的組合包裝。除了奈瑪特韋原料藥或製劑的生產授權以外,作為Paxlovid成分之一的利托那韋也同樣值得重點關注。在利托那韋的供應商之中,歌禮制藥通過多年的不懈努力,使用高端製劑技術,大幅度提高難溶性利托那韋在人體內的生物利用度,從而達到了與艾伯維生產的原研口服片在人體中的生物等效。歌禮制藥的利托那韋片於2021年9月獲中國國家藥品監督管理局批准上市,是中國唯一通過生物等效性研究並獲批上市的利托那韋片。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account